This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007). All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, web-based, consumer panel via opt-in e-mails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. All respondents explicitly agree to be a panel member, register with the panel through a unique e-mail address, and complete an in-depth demographic registration profile. This analysis will focus on respondents who self-report having migraine diagnosed by a physician. Individuals who use rimegepant for acute treatment of migraine will be compared with those who use triptans for acute treatment of migraine. Outcomes of interest include treatment satisfaction, healthcare resource utilization (HCRU), quality of life (QoL), work productivity loss, and migraine-specific disability outcomes. Inverse probability of treatment weighting (IPTW) will be used to adjust for differences that may exist between rimegepant and triptan users prior to comparing outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC])
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Migraine Treatment Type (Acute or Prevention)
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Total Number of Acute Migraine Agent Drug Classes Used
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Number of Acute Migraine Agent Drug Classes Used
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Total Number of Prevention Migraine Agent Drug Classes Used
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Current Migraine Treatments
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Current Migraine Treatments on OTC Class
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Primary Analysis
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Index Score - Primary Analysis
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
EQ-5D-5L Visual Analog Scale (VAS) Score - Primary Analysis
Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Percentage of Work Time Missed in Past 7 Days Based on Work Productivity and Activity Impairment - General Health (WPAI-GH) Questionnaire- Primary Analysis
Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Percentage Impairment Experienced While at Work in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Percentage Overall Work Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
Timeframe: 3 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants According to MIDAS Grade- Primary Analysis
Timeframe: 3 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of ER Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Mean Number of Hospitalizations in Past 6 Months - Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Mean Number of Family Practitioner Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Mean Number of Cardiologist Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 month of this observational study.
Mean Number of Neurologist Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.
Mean Number of Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis
Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.